TG Therapeutics
TGTX
214 hedge funds and large institutions have $1.43B invested in TG Therapeutics in 2023 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 61 increasing their positions, 62 reducing their positions, and 35 closing their positions.
99% more call options, than puts
Call options by funds: $41.9M | Put options by funds: $21.1M
54% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 35
29% more capital invested
Capital invested by funds: $1.11B → $1.43B (+$317M)
9% more funds holding
Funds holding: 197 → 214 (+17)
0.59% more ownership
Funds ownership: 64.24% → 64.83% (+0.59%)
2% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$159M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$77.5M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$16.7M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$15.2M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$54.2M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$51.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$42.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$32.3M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$30.3M |
TGTX Hedge Fund Activity: Q1 2023 in Review
214 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2023, worth a combined $1.43B — up 29% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new TGTX positions and 35 closed out — a net gain of 19 holders — while 61 added to existing stakes and 62 trimmed.
The largest buyer was Darwin Global Management, opening a new position worth an estimated $159M. The largest seller was Millennium Management, cutting an estimated $54.2M.
- 214 institutional investors held TG Therapeutics (TGTX) as of Q1 2023, up from 197 in Q4 2022.
- Funds reported $1.43B of TG Therapeutics stock for Q1 2023, up 29% quarter-over-quarter.
- 54 funds opened new TG Therapeutics positions in Q1 2023 and 35 closed out, a net change of +19 holders.
- The largest TG Therapeutics buyer in Q1 2023 was Darwin Global Management, an estimated $159M added.
- The largest TG Therapeutics seller in Q1 2023 was Millennium Management, an estimated $54.2M sold.
Based on aggregated 13F filings for Q1 2023.